Barr’s Allegra-D Generic Eligible For Final Approval, Sole Exclusivity

Company is withdrawing its Paragraph IV certification against a late-listed Sanofi-Aventis patent for the fexofenadine/pseudoephedrine 12-hour formulation, clearing the way for final approval of its ANDA. Any launch would be “at risk” due to pending patent litigation.